| Business Summary | | Neurobiological
Technologies,
Inc.
is
an
emerging
drug
development
company
focused
on
the
clinical
evaluation
and
regulatory
approval
of
neuroscience
drugs.
The
Company
develops
neuroprotective
and
neuromodulatory
agents
to
treat
progressive
neurological
impairments
characteristic
of
various
nervous
system
disorders,
including
diabetic
neuropathy,
brain
cancer,
and
AIDS
dementia
syndrome.
The
Company's
strategy
is
to
in-license
and
develop
early-stage
drug
candidates
that
target
major
medical
needs
and
which
can
be
rapidly
commercialized.
The
Company's
products
in
development
include
Memantine
and
XERECEPT. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Neurobiological
Technologies
is
a
development
stage
drug
development
company
focused
on
the
clinical
evaluation
and
regulatory
approval
of
neuroscience
drugs.
NTI
strategy
is
to
in-license
and
develop
early-stage
drug
candidates
that
target
major
medical
needs.
For
the
nine
months
ended
3/31/00,
revenue
totaled
$2.5
million
vs.
none.
Net
income
totaled
$63
thousand
vs.
a
loss
of
$2.3
million.
Results
reflect
higher
license
income,
and
lower
research
and
development
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,250;
after
tax
earnings
were
1,525. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Abraham Cohen, 64 Chairman
of Directors | -- | -- | Paul Freiman, 66 Pres
and CEO | $155K | $356K | Lisa Carr, M.D., Ph.D., 45 VP,
Medical Affairs | 103K | 229K | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|